Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Zomedica Corp. (ZOMDF) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret the information. Zomedica is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals, and its SEC filings offer detailed insight into how it reports financial performance, risks, and strategic priorities.
Investors can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment discussions for diagnostics, therapeutic devices, and development services, as well as commentary on consumable and capital revenue, margins, liquidity, and operating expenses. Current reports on Form 8-K, such as the filing dated November 4, 2025 referencing a press release on quarterly results, disclose material events and financial updates between regular reporting periods.
The platform also surfaces proxy statements and other governance-related documents, where available, and Form 4 insider transaction reports that show purchases and sales by directors and officers. These documents can be important for understanding executive incentives and ownership changes.
AI-powered tools on this page summarize lengthy filings, highlight key sections, and explain complex accounting or risk disclosures in plain language. Real-time connections to the SEC’s EDGAR system help ensure new filings appear promptly, so users can quickly locate the latest 10-K, 10-Q, 8-K, and Form 4 documents for Zomedica. This structure allows both individual and professional investors to navigate Zomedica’s regulatory history and evaluate its reported progress in animal health diagnostics and therapeutics.
Zomedica Corp. (ZOMDF) reported a new equity award to one of its directors. The director received a stock appreciation right1,975,033 underlying common shares at a conversion or exercise price of $0.1 per share in a transaction on 11/17/2025 coded as an acquisition. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Following this grant, the director beneficially owns 1,975,033 derivative securities directly, all tied to Zomedica common stock.
Zomedica Corp. (ZOMDF)11/17/2025, reporting person Johnny Powers acquired 1,823,107 stock appreciation rights, each linked to one share of Zomedica common stock. The rights have a conversion or exercise price of $0.10 per share, with a vesting or exercisability date of 11/16/2026 and an expiration date of 11/16/2035. Following this grant, Powers beneficially owns 1,823,107 derivative securities directly, giving him economic exposure to the same number of Zomedica common shares if the stock price rises above the exercise price.
Zomedica Corp. (ZOMDF) reported an insider equity award for a company director. The filing shows the grant of a stock appreciation right covering 1,823,107 shares of common stock on 11/17/2025. The right has a conversion or exercise price of $0.10 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities, held in direct ownership.
Zomedica Corp. (ZOMDF) reported a change in director equity holdings on a Form 4. On 11/17/2025, a director acquired a stock appreciation right covering 1,823,107 derivative securities at a conversion or exercise price of $0.10 per underlying share. The derivative security is linked to 1,823,107 shares of common stock, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities with direct ownership reported.
Zomedica Corp. director reports stock appreciation right grant. A company director filed a Form 4 disclosing the award of a stock appreciation right covering 1,823,107 shares of Zomedica common stock on 11/17/2025. The derivative security has an exercise price of $0.1 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities directly, each tied to one share of common stock.
Zomedica Corp. (ZOMDF)Rodney J. Williams. On 11/17/2025, he received a stock appreciation right covering 1,975,033 derivative securities with a conversion or exercise price of $0.1. The right becomes exercisable on 11/16/2026 and expires on 11/16/2035, and is linked to 1,975,033 shares of common stock. Following this grant, he beneficially owned 1,975,033 derivative securities, held in direct ownership.
Zomedica Corp. (ZOMDF)2,126,959 stock appreciation rights with a conversion or exercise price of $0.1 per right. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Each right is linked to one share of common stock, so the transaction covers 2,126,959 underlying common shares. Following this grant, the director beneficially owns 2,126,959 derivative securities, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on a Form 4. Senior Vice President, Sales, Kevin Klass bought 150,000 shares of common stock on November 13, 2025 at $0.097 per share. Following the transaction, he beneficially owned 5,784,101 shares, held directly.
Zomedica Corp. (ZOMDF) reported an insider purchase on Form 4. Kevin Klass, Sr Vice President, Sales, bought 120,000 shares of common stock on 11/10/2025 at $0.098 per share (transaction code P). Following this trade, he directly holds 5,634,101 shares.
Zomedica Corp. (ZOMDF)
FAQ
What is the current stock price of Zomedica (ZOMDF)?
What is the market cap of Zomedica (ZOMDF)?
